The aim of this commentary is to discuss the published Cochrane Review “Belimumab for systemic lupus erythematosus”1 by Singh et al.,a under the direct supervision of Cochrane Musculoskeletal Group. This Cochrane Corner is produced in agreement with International Journal of Rheumatic Diseases by Cochrane Rehabilitation.
What are the benefits and harms of belimumab for patients with systemic lupus erythematosus?: A Cochrane Review summary with commentary
Iolascon, Giovanni
2021
Abstract
The aim of this commentary is to discuss the published Cochrane Review “Belimumab for systemic lupus erythematosus”1 by Singh et al.,a under the direct supervision of Cochrane Musculoskeletal Group. This Cochrane Corner is produced in agreement with International Journal of Rheumatic Diseases by Cochrane Rehabilitation.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
